| アブストラクト | PURPOSE: We compared health service utilization and costs for patients with epilepsy before and after initiation of perampanel and compared with matched controls. METHOD: Patients were selected from the Clinical Practice Research Datalink (CPRD). Patients initiating perampanel were matched to controls initiating an alternate add-on therapy for the same underlying epilepsy subtype. First prescription defined index date. Primary and secondary care contacts and associated costs were aggregated in the 12months before and after index date. Secondary care contacts were available for a subset (~60%) of patients. RESULTS: Three hundred and forty-three patients treated with perampanel were identified. One hundred and eighty-three (53.4%) were male, mean age was 39.1 (sd: 16.0). Mean epilepsy duration was 21.1 (standard deviation (sd): 13.3) years. Two hundred and eighty-seven (83.7%) were matched to controls. Inpatient admissions with a primary diagnosis of epilepsy (0.5 versus 0.2 per patient-year (ppy), p=0.002) and neurology specific outpatient appointments (3.2 versus 2.9 ppy, p=0.041) were significantly reduced following initiation with perampanel. Total costs attributable to epilepsy ( pound1889 to 1477 ppy) and overall secondary costs ( pound2593 to pound2102) were also significantly reduced. There was no significant difference in primary care, outpatient, or general inpatient admissions. Compared with controls, there was a significant reduction in primary epilepsy admissions (incidence rate ratio (IRR): 0.423; 95% Confidence intervals (CI): 0.198-0.835) but a significant increase in outpatient appointments (1.306; 95% CI: 1.154-1.478) and accident and emergency contacts (1.603; 95% CI: 1.081-2.390) for patients treated with perampanel. CONCLUSION: Treatment with perampanel is associated with reduced epilepsy-related inpatient admissions and accident and emergency contacts. |
|---|
| ジャーナル名 | Epilepsy & behavior : E&B |
|---|
| 投稿日 | 2020/6/1 |
|---|
| 投稿者 | Morgan, Christopher Ll; Varga, Stefan; Tsong, Wan; Jenkins-Jones, Sara; Holden, Sarah |
|---|
| 組織名 | Pharmatelligence, Cardiff, UK. Electronic address:;Chris.morgan@pharmatelligence.co.uk.;Formerly Eisai Inc., Woodcliff Lake, NJ, USA.;Pharmatelligence, Cardiff, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/32474360/ |
|---|
